Benitec Biopharma (NASDAQ:BNTC) Releases Earnings Results, Beats Expectations By $0.19 EPS

Benitec Biopharma (NASDAQ:BNTC) issued its quarterly earnings results on Friday. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19, Zacks reports.

Benitec Biopharma Stock Performance

BNTC opened at $11.25 on Friday. Benitec Biopharma has a 12 month low of $2.75 and a 12 month high of $13.29. The stock’s 50 day moving average price is $11.38 and its 200 day moving average price is $10.23.

Analyst Ratings Changes

A number of brokerages recently commented on BNTC. Robert W. Baird began coverage on Benitec Biopharma in a report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price target for the company. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. HC Wainwright initiated coverage on Benitec Biopharma in a report on Monday, December 16th. They set a “buy” rating and a $28.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $17.00 target price on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Finally, Baird R W raised Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Benitec Biopharma has an average rating of “Buy” and a consensus price target of $24.43.

Insider Activity at Benitec Biopharma

In other Benitec Biopharma news, Director Suvretta Capital Management, L bought 27,502 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $10.98 per share, for a total transaction of $301,971.96. Following the transaction, the director now directly owns 7,981,725 shares in the company, valued at $87,639,340.50. The trade was a 0.35 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is owned by insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.